Welcome to our dedicated page for AdaptHealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp. agreed on July 19, 2026 to sell substantially all assets of its Diabetes Health business to RGH Enterprises, LLC, a Cardinal Health subsidiary, for $235 million in cash, subject to a net working capital adjustment. The buyer will assume specified liabilities, and will place $8.0 million of the price in escrow for post-closing adjustments and $18.8 million to secure AdaptHealth’s indemnification obligations. Closing conditions include antitrust clearance under the Hart-Scott-Rodino Act and other competition and healthcare laws, absence of legal prohibitions or a material adverse effect on the business, accuracy of representations and covenants, completion of a separation plan, and acceptance of employment offers by at least 80% of offered employees including a key employee.
The agreement includes a four-year non-compete in North America, a two-year non-solicitation covenant for transferred personnel, and a seven-year confidentiality obligation. It can be terminated for customary reasons, including failure to close within 12 months; in certain antitrust-related terminations, the purchaser must pay AdaptHealth a $9.4 million fee. Following closing, the Diabetes Health business will be reported as discontinued operations. Management describes the divestiture as a significant step in a multi-year plan to focus on core Sleep Health, Respiratory Health and Wellness at Home segments, redeploy capital toward these areas, and further strengthen the balance sheet, with more detail to be provided on the August 4, 2026 earnings call.
AdaptHealth Corp. announced that its subsidiary AdaptHealth LLC plans to redeem all outstanding 6.125% Senior Notes due 2028 with an aggregate principal amount of $325,000,000. The notes are expected to be redeemed at 100% of principal plus accrued and unpaid interest up to, but not including, the redemption date.
The redemption is conditioned on receiving sufficient net proceeds from a borrowing under the Issuer’s existing delayed draw term loan facility. The redemption date is expected to be August 1, 2026, with payment of the redemption price expected on the next business day, August 3, 2026, after which interest will no longer accrue on the notes.
AdaptHealth Corp. Chief Commercial Officer Russell E. Schuster III reported an open-market sale of 11,275 shares of Common Stock on July 1, 2026 at $10.44 per share. The filing shows he now directly holds 125,263 shares after the transaction.
The sale occurred automatically under a Rule 10b5-1 trading plan that Schuster adopted on March 2, 2026, indicating the trade was pre-scheduled rather than a discretionary market-timing decision.
AdaptHealth Corp. reports a material cybersecurity incident involving patient data. A threat actor gained unauthorized access to certain cloud-based business applications, including internal patient management systems and document storage platforms, via a social engineering attack on a third-party contractor’s user session.
The company confirmed exfiltration of a stored password file tied to insurance billing and access to external electronic health record portals, affecting passwords and some patients’ personally identifiable and protected health information. The affected systems do not contain Social Security numbers or individual financial account or payment card data.
AdaptHealth has disabled the compromised account, reset credentials, added access controls, engaged external cybersecurity experts and notified law enforcement. As of this report, operations and patient services have not been materially impacted, though the full scope of data involved and the financial impact remain under investigation. The company notes that cybersecurity insurance may cover certain losses.
AHCO filed a Form 144 reporting an intent to sell 11,275 shares of Common Stock. The shares are listed as resulting from Restricted Stock Vesting dated 02/01/2026 and are associated with compensation. The filing shows a prior reported sale of 11,275 shares on 06/01/2026 and lists Fidelity Brokerage Services LLC as the broker. Transaction specifics and cash‑flow treatment are stated in the filing entries.
AdaptHealth Corp. director David Solomon Williams III received a grant of 18,999 shares of common stock on June 24, 2026, recorded as restricted stock units that will settle in common shares upon vesting. The grant carried a price of $0.00 per share, reflecting equity-based compensation rather than a market purchase. Following this award, Williams has 64,044 shares of AdaptHealth common stock reported as directly owned, indicating this filing reflects a compensation-related acquisition, not an open-market transaction.
Weaver Susan T reported acquisition or exercise transactions in this Form 4 filing.
AdaptHealth Corp. director Susan T. Weaver reported a stock-based compensation award rather than an open-market trade. She received 18,999 shares of Common Stock in the form of restricted stock units at $0.00 per share, bringing her direct holdings to 40,345 shares. A separate line shows 73,472 shares of Common Stock held indirectly through the Susan T. Weaver 2025 Irrevocable Trust, for which her spouse and son are co-trustees and her spouse and children are beneficiaries. The restricted stock units will be settled in common stock upon vesting.
AdaptHealth Corp. director Terence J. Connors received an equity grant in the form of restricted stock units. On June 24, 2026, he was awarded 18,999 shares of Common Stock at no cash cost as a grant or award acquisition. These restricted stock units will be settled in common stock when they vest. Following this transaction, Connors directly holds 95,262 shares of AdaptHealth Common Stock, reflecting his updated equity position with the company.
BELINFANTI GREGORY reported acquisition or exercise transactions in this Form 4 filing.
AdaptHealth Corp. director Gregory Belinfanti received an equity grant in the form of restricted stock units. He was awarded 18,999 shares of common stock at no purchase price, increasing his direct holdings to 104,269 shares following the grant. The units will settle in common stock upon vesting.
Coppens Bradley J reported acquisition or exercise transactions in this Form 4 filing.
AdaptHealth Corp. director Bradley J. Coppens reported receiving a grant of 18,999 shares of Common Stock in the form of restricted stock units, which will be settled in common stock upon vesting. Following this award, he directly holds a total of 96,345 shares.